AKT1 and acute lymphoblastic leukemia: TRIM37 promoted the proliferation of T-ALL cells and reduced the sensitivity to bortezomib of T-ALL cells at least in part through the excessive activation of PI3K/Akt signaling pathway and by ubiquitination of PTEN, suggesting TRIM37 might be used as therapeutic targets for T-ALL treatment.